Type 2 conventional dendritic cells limit responsiveness to cancer immunotherapy (#241)
Nayvin W Chew
1
2
,
Shayan C. Avanessian
2
3
,
Renske J.E. van den Bijgaart
2
,
Yogesh Kushwaha
2
,
Thao T. Tang
2
,
Tomas Bencomo
4
,
Carolyn Shasha
5
,
Lauren E. Martin
6
,
Kokoro Abe
7
,
Jordan Gauthier
7
8
,
Aude G. Chapuis
6
,
Paul Nghiem
4
,
Anthony Rongvaux
6
,
Evan Newell
5
,
Kevin C. Barry
1
2
3
- Department of Immunology, University of Washington, Seattle, WA, 98109, United States
- Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States
- Program in Molecular and Cellular Biology, University of Washington, Seattle, WA, 98195, United States
- Department of Dermatology, University of Washington, Seattle, WA, 98195, United States
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States
- Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States
- Department of Medicine, University of Washington, Seattle, WA, 98195, United States